LUCY READING-IKKANDA
Sangamo Biosciences is putting a different spin on gene therapy. Rather than replace or supplement a mutated gene with an accurate copy, Sangamo researchers are introducing a mutant copy of the gene for the HIV co-receptor CCR5 into the T cells of HIV patients. This prevents the expression of CCR5 on the cell’s surface, and thus inhibits HIV from infecting cells.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!